Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL24009697 | 1.00 | DRD2 (0.41) | DRD2DRD3 | |
| Hydrochloric Acid SCHEMBL29014048 | 0.99 | DRD2 (0.40) | DRD2DRD3 | |
| Hydrochloric Acid SCHEMBL29014046 | 0.99 | DRD2 (0.40) | DRD2DRD3 | |
| SCHEMBL31313807 | 0.94 | DRD2 (0.40) | DRD2DRD3 | |
| SCHEMBL27167010 | 0.92 | CHRNB2 (0.34) | DRD2DRD3 | |
| SCHEMBL31313914 | 0.89 | DRD2 (0.40) | DRD2DRD3 | |
| Trifluoroacetic Acid SCHEMBL31411018 | 0.88 | SLC6A3 (0.41) | — | |
| SCHEMBL24001938 | 0.80 | CHEK1 (0.49) | DRD2DRD3 | |
| SCHEMBL24001714 | 0.80 | CHEK1 (0.49) | DRD2DRD3 | |
| SCHEMBL19680559 | 0.80 | CHEK1 (0.49) | DRD2DRD3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 22 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4727934-A1 | TREM2 AGONISTS | F. Hoffmann-La Roche AG (CH) | 2026-04-22 | — | — | EP | disclosed |
| US-20250304580-A1 | HETEROCYCLIC COMPOUNDS AS TRIGGERING RECEPTOR EXPRESSED ON MYELOID CELLS 2 AGONISTS AND METHODS OF USE | VIGIL NEUROSCIENCE, INC. (US) | 2025-10-02 | — | — | US | disclosed |
| EP-4551575-A2 | TREM2 MODULATORS | Muna Therapeutics ApS (DK) | 2025-05-14 | — | — | EP | disclosed |
| CN-119403806-A | TREM2 modulators | 穆纳治疗有限公司 | 2025-02-07 | — | — | CN | disclosed |
| US-20250042897-A1 | HETEROCYCLIC COMPOUNDS AS TRIGGERING RECEPTOR EXPRESSED ON MYELOID CELLS 2 AGONISTS AND METHODS OF USE | VIGIL NEUROSCIENCE, INC. (US) | 2025-02-06 | — | — | US | disclosed |
| WO-2024260929-A1 | TREM2 AGONISTS | F. HOFFMANN-LA ROCHE AG (CH) | 2024-12-26 | — | — | WO | disclosed |
| WO-2024233848-A1 | HETEROCYCLIC COMPOUNDS AS TRIGGERING RECEPTOR EXPRESSED ON MYELOID CELLS 2 AGONISTS AND METHODS OF USE | VIGIL NEUROSCIENCE, INC. (US) | 2024-11-14 | — | — | WO | disclosed |
| EP-4430029-A1 | HETEROCYCLIC COMPOUNDS AS TRIGGERING RECEPTOR EXPRESSED ON MYELOID CELLS 2 AGONISTS AND METHODS OF USE | Vigil Neuroscience, Inc. (US) | 2024-09-18 | — | — | EP | disclosed |
| US-11912711-B2 | Heterocyclic compounds as triggering receptor expressed on myeloid cells 2 agonists and methods of use | AMGEN INC. (US) | 2024-02-27 | — | — | US | disclosed |
| US-11912711-B2 | Heterocyclic compounds as triggering receptor expressed on myeloid cells 2 agonists and methods of use | AMGEN INC. (US) | 2024-02-27 | — | — | US | disclosed |
| WO-2024008722-A2 | TREM2 MODULATORS | MUNA THERAPEUTICS APS (DK) | 2024-01-11 | — | — | WO | disclosed |
| US-20230295169-A1 | HETEROCYCLIC COMPOUNDS AS TRIGGERING RECEPTOR EXPRESSED ON MYELOID CELLS 2 AGONISTS AND METHODS OF USE | AMGEN INC. | 2023-09-21 | — | — | US | disclosed |
| US-20230295169-A1 | HETEROCYCLIC COMPOUNDS AS TRIGGERING RECEPTOR EXPRESSED ON MYELOID CELLS 2 AGONISTS AND METHODS OF USE | AMGEN INC. | 2023-09-21 | — | — | US | disclosed |
| US-20230295170-A1 | HETEROCYCLIC COMPOUNDS AS TRIGGERING RECEPTOR EXPRESSED ON MYELOID CELLS 2 AGONISTS AND METHODS OF USE | AMGEN INC. | 2023-09-21 | — | — | US | disclosed |
| US-20230295170-A1 | HETEROCYCLIC COMPOUNDS AS TRIGGERING RECEPTOR EXPRESSED ON MYELOID CELLS 2 AGONISTS AND METHODS OF USE | AMGEN INC. | 2023-09-21 | — | — | US | disclosed |
| WO-2023086800-A1 | HETEROCYCLIC COMPOUNDS AS TRIGGERING RECEPTOR EXPRESSED ON MYELOID CELLS 2 AGONISTS AND METHODS OF USE | VIGIL NEUROSCIENCE, INC. (US) | 2023-05-19 | — | — | WO | disclosed |
| WO-2023086800-A1 | HETEROCYCLIC COMPOUNDS AS TRIGGERING RECEPTOR EXPRESSED ON MYELOID CELLS 2 AGONISTS AND METHODS OF USE | VIGIL NEUROSCIENCE, INC. (US) | 2023-05-19 | — | — | WO | disclosed |
| WO-2023086801-A1 | HETEROCYCLIC COMPOUNDS AS TRIGGERING RECEPTOR EXPRESSED ON MYELOID CELLS 2 AGONISTS AND METHODS OF USE | VIGIL NEUROSCIENCE, INC. (US) | 2023-05-19 | — | — | WO | disclosed |
| CN-115867284-A | Heterocyclic compounds as trigger receptor 2 agonists expressed on myeloid cells and methods of use | 安进公司 | 2023-03-28 | — | — | CN | disclosed |
| US-20230002390-A1 | HETEROCYCLIC COMPOUNDS AS TRIGGERING RECEPTOR EXPRESSED ON MYELOID CELLS 2 AGONISTS AND METHODS OF USE | AMGEN INC. | 2023-01-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250304580-A1 | HETEROCYCLIC COMPOUNDS AS TRIGGERING RECEPTOR EXPRESSED ON MYELOID CELLS 2 AGONISTS AND METHODS OF USE | MSR1, FPR2, CD14 | DRD2 1052/4885DRD3 2484/4885 |
| US-20230002390-A1 | HETEROCYCLIC COMPOUNDS AS TRIGGERING RECEPTOR EXPRESSED ON MYELOID CELLS 2 AGONISTS AND METHODS OF USE | MSR1, FPR2, CD14 | DRD2 1052/4885DRD3 2484/4885 |
| US-11912711-B2 | Heterocyclic compounds as triggering receptor expressed on myeloid cells 2 agonists and methods of use | MSR1, FPR2, CD14 | DRD2 1052/4885DRD3 2484/4885 |
| US-20230295169-A1 | HETEROCYCLIC COMPOUNDS AS TRIGGERING RECEPTOR EXPRESSED ON MYELOID CELLS 2 AGONISTS AND METHODS OF USE | MSR1, FPR2, CD14 | DRD2 1052/4885DRD3 2484/4885 |
| US-20230295170-A1 | HETEROCYCLIC COMPOUNDS AS TRIGGERING RECEPTOR EXPRESSED ON MYELOID CELLS 2 AGONISTS AND METHODS OF USE | MSR1, FPR2, CD14 | DRD2 1052/4885DRD3 2484/4885 |
| US-20250042897-A1 | HETEROCYCLIC COMPOUNDS AS TRIGGERING RECEPTOR EXPRESSED ON MYELOID CELLS 2 AGONISTS AND METHODS OF USE | MSR1, FPR2, CD14 | DRD2 1375/4885DRD3 2973/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.